|This article is part of MPR‘s coverage of IDWeek 2018, taking place in San Francisco, CA. Our on-site staff will be reporting on the latest breaking research and clinical advances in infectious diseases. Check back regularly for highlights from IDWeek 2018.|
SAN FRANCISCO — The incidence of body fat redistribution/accumulation, pancreatic disorders, musculoskeletal disorders, immune reconstitution inflammatory syndrome, severe systemic rash, and hypersensitivity reactions did not differ among common prescribed antiretrovirals, according to the results of a study presented at ID Week 2018, held October 3 to 7, 2018, in San Francisco, California.
Dolutegravir, elvitegravir, raltegravir, and darunavir are commonly prescribed antiretrovirals used for the treatment of HIV. Unfortunately, these antiretrovirals have been associated with 6 disorders after initiation. Better understanding HIV-related comorbidities and complications that are associated with antiretroviral regimens could lead to more effective management and result in a higher treatment adherence with antiretroviral regimens, patient satisfaction, and better virologic outcomes. Therefore, this study assessed the frequency of 6 select disorders after prescription of dolutegravir-, elvitegravir-, raltegravir-, or darunavir-based regimens.
A total of 22,674 HIV-positive patients in the OPERA Observational Database initiating dolutegravir-, elvitegravir-, raltegravir-, or darunavir-containing regimens were included. Most patients were male, had previous antiretroviral therapy experience, a HIV viral load of <100,000, and a CD4 cell count of ≥200, and did not have a history of AIDS. The disorders of interest included: body fat redistribution/accumulation, pancreatic disorders, musculoskeletal disorders, immune reconstitution inflammatory syndrome, severe systemic rash, and hypersensitivity reactions. Body fat redistribution/accumulation was the diagnosis of lipohypertrophy, lipoaccumulation, hyperadiposity, lipoatrophy, or lipodystrophy. Pancreatic disorders included the diagnosis of pancreatitis or a pancreatic adverse elevation (lipase >3 times upper limit of normal). Musculoskeletal disorders included the diagnosis of rhabdomyolysis or musculoskeletal adverse elevations (creatine phosphokinase ≥10 times the upper limit of normal). The proportion of patients with 1 of these disorders of interest during follow-up were compared between core agents for each disorder. To account for multiple comparisons, the Sidak Correction was applied (adjusted alpha level .017).
Among participants, 35% initiated dolutegravir, 43% initiated elvitegravir, 7% initiated raltegravir, and 15% initiated darunavir. Results showed that the likelihood of new events did not differ significantly by core agent. Results showed that history body fat redistribution/accumulation was less frequent in patients initiating elvitegravir and more frequent in patients initiating raltegravir compared with dolutegravir. Elvitegravir users also had a lower prevalence of body fat redistribution/accumulation than dolutegravir users at follow-up. However, there was no difference in new onset of body fat redistribution/accumulation between groups. Further, neither the prevalence nor incidence of pancreatic or musculoskeletal disorders showed a difference between core agents. Severe systemic rash, hypersensitivity reaction, or immune reconstitution inflammatory syndrome did not occur in more than 2 patients per core agent group and there were no differences detected in these disorders between groups.
Overall, the study authors concluded that, “Despite some channeling of patients with a disorder history towards dolutegravir and raltegravir use, the likelihood of new events did not differ by core agent.”
|Visit MPR‘s conference section for continuous coverage live from IDWeek 2018.|
Lackey P, Brunet L, Fusco J, Vannappagari V, Ragone L, Fusco G. Body fat redistribution/accumulation, pancreatic disorders, musculoskeletal disorders, IRIS, severe systemic rash, and hypersensitivity reactions following initiation of commonly prescribed antiretrovirals. Presented at: IDWeek 2018; October 3-7, 2018; San Francisco, CA. Poster 936.
This article originally appeared on Infectious Disease Advisor